New developments in systemic lupus erythematosus.

Rheumatology (Oxford) · 2021 · PMC8709564 · PMID 34951924

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

At the primary end point at week 12, the SRI4 response rates were 55% for IL-2 and 30% for placebo, which did not reach statistical significance.

also in 111,027 other papers

showed a trendno p-value reported

Subjects receiving omalizumab showed a trend toward improvement in IFN gene signature.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.